The global Combination Vaccine and Multivalent Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Combination Vaccine and Multivalent Vaccine in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Combination Vaccine and Multivalent Vaccine include Merck & Co., Pfizer, Sanofi Pasteur, GlaxoSmithKline, BioNTech, Moderna, Dynavax, Novavax, Sino Biopharm, Kangtai Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Combination Vaccine and Multivalent Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Combination Vaccine and Multivalent Vaccine.
The Combination Vaccine and Multivalent Vaccine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Combination Vaccine and Multivalent Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Combination Vaccine and Multivalent Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co.
Pfizer
Sanofi Pasteur
GlaxoSmithKline
BioNTech
Moderna
Dynavax
Novavax
Sino Biopharm
Kangtai Bio
Zhifei Biological
Walvax
Minhai Biological
Sinovac
Wantai Biological
Wanbangde Pharmaceutical
AIM Bio
Antejin Biotechnology
Lanzhou Institute of Biological Products
Wuhan Institute of Biological Products
Beijing Institute of Biological Products
Chengdu Institute of Biological Products
Segment by Type
Combination Vaccine
Multivalent Vaccine
Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Combination Vaccine and Multivalent Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Combination Vaccine
1.2.3 Multivalent Vaccine
1.3 Market by Application
1.3.1 Global Combination Vaccine and Multivalent Vaccine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Centers for Disease Control and Prevention
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Combination Vaccine and Multivalent Vaccine Market Perspective (2019-2030)
2.2 Global Combination Vaccine and Multivalent Vaccine Growth Trends by Region
2.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Combination Vaccine and Multivalent Vaccine Historic Market Size by Region (2019-2024)
2.2.3 Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Region (2025-2030)
2.3 Combination Vaccine and Multivalent Vaccine Market Dynamics
2.3.1 Combination Vaccine and Multivalent Vaccine Industry Trends
2.3.2 Combination Vaccine and Multivalent Vaccine Market Drivers
2.3.3 Combination Vaccine and Multivalent Vaccine Market Challenges
2.3.4 Combination Vaccine and Multivalent Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue
3.1.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue (2019-2024)
3.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Combination Vaccine and Multivalent Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Combination Vaccine and Multivalent Vaccine Revenue
3.4 Global Combination Vaccine and Multivalent Vaccine Market Concentration Ratio
3.4.1 Global Combination Vaccine and Multivalent Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Combination Vaccine and Multivalent Vaccine Revenue in 2023
3.5 Global Key Players of Combination Vaccine and Multivalent Vaccine Head office and Area Served
3.6 Global Key Players of Combination Vaccine and Multivalent Vaccine, Product and Application
3.7 Global Key Players of Combination Vaccine and Multivalent Vaccine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Combination Vaccine and Multivalent Vaccine Breakdown Data by Type
4.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Type (2019-2024)
4.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Type (2025-2030)
5 Combination Vaccine and Multivalent Vaccine Breakdown Data by Application
5.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Application (2019-2024)
5.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Combination Vaccine and Multivalent Vaccine Market Size (2019-2030)
6.2 North America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
6.4 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Combination Vaccine and Multivalent Vaccine Market Size (2019-2030)
7.2 Europe Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
7.4 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size (2019-2030)
8.2 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Region (2019-2024)
8.4 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Combination Vaccine and Multivalent Vaccine Market Size (2019-2030)
9.2 Latin America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
9.4 Latin America Combination Vaccine and Multivalent Vaccine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size (2019-2030)
10.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2019-2024)
10.4 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck & Co.
11.1.1 Merck & Co. Company Details
11.1.2 Merck & Co. Business Overview
11.1.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Introduction
11.1.4 Merck & Co. Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.1.5 Merck & Co. Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Combination Vaccine and Multivalent Vaccine Introduction
11.2.4 Pfizer Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Company Details
11.3.2 Sanofi Pasteur Business Overview
11.3.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Introduction
11.3.4 Sanofi Pasteur Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.3.5 Sanofi Pasteur Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Introduction
11.4.4 GlaxoSmithKline Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 BioNTech
11.5.1 BioNTech Company Details
11.5.2 BioNTech Business Overview
11.5.3 BioNTech Combination Vaccine and Multivalent Vaccine Introduction
11.5.4 BioNTech Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.5.5 BioNTech Recent Development
11.6 Moderna
11.6.1 Moderna Company Details
11.6.2 Moderna Business Overview
11.6.3 Moderna Combination Vaccine and Multivalent Vaccine Introduction
11.6.4 Moderna Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.6.5 Moderna Recent Development
11.7 Dynavax
11.7.1 Dynavax Company Details
11.7.2 Dynavax Business Overview
11.7.3 Dynavax Combination Vaccine and Multivalent Vaccine Introduction
11.7.4 Dynavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.7.5 Dynavax Recent Development
11.8 Novavax
11.8.1 Novavax Company Details
11.8.2 Novavax Business Overview
11.8.3 Novavax Combination Vaccine and Multivalent Vaccine Introduction
11.8.4 Novavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.8.5 Novavax Recent Development
11.9 Sino Biopharm
11.9.1 Sino Biopharm Company Details
11.9.2 Sino Biopharm Business Overview
11.9.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Introduction
11.9.4 Sino Biopharm Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.9.5 Sino Biopharm Recent Development
11.10 Kangtai Bio
11.10.1 Kangtai Bio Company Details
11.10.2 Kangtai Bio Business Overview
11.10.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Introduction
11.10.4 Kangtai Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.10.5 Kangtai Bio Recent Development
11.11 Zhifei Biological
11.11.1 Zhifei Biological Company Details
11.11.2 Zhifei Biological Business Overview
11.11.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Introduction
11.11.4 Zhifei Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.11.5 Zhifei Biological Recent Development
11.12 Walvax
11.12.1 Walvax Company Details
11.12.2 Walvax Business Overview
11.12.3 Walvax Combination Vaccine and Multivalent Vaccine Introduction
11.12.4 Walvax Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.12.5 Walvax Recent Development
11.13 Minhai Biological
11.13.1 Minhai Biological Company Details
11.13.2 Minhai Biological Business Overview
11.13.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Introduction
11.13.4 Minhai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.13.5 Minhai Biological Recent Development
11.14 Sinovac
11.14.1 Sinovac Company Details
11.14.2 Sinovac Business Overview
11.14.3 Sinovac Combination Vaccine and Multivalent Vaccine Introduction
11.14.4 Sinovac Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.14.5 Sinovac Recent Development
11.15 Wantai Biological
11.15.1 Wantai Biological Company Details
11.15.2 Wantai Biological Business Overview
11.15.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Introduction
11.15.4 Wantai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.15.5 Wantai Biological Recent Development
11.16 Wanbangde Pharmaceutical
11.16.1 Wanbangde Pharmaceutical Company Details
11.16.2 Wanbangde Pharmaceutical Business Overview
11.16.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Introduction
11.16.4 Wanbangde Pharmaceutical Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.16.5 Wanbangde Pharmaceutical Recent Development
11.17 AIM Bio
11.17.1 AIM Bio Company Details
11.17.2 AIM Bio Business Overview
11.17.3 AIM Bio Combination Vaccine and Multivalent Vaccine Introduction
11.17.4 AIM Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.17.5 AIM Bio Recent Development
11.18 Antejin Biotechnology
11.18.1 Antejin Biotechnology Company Details
11.18.2 Antejin Biotechnology Business Overview
11.18.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Introduction
11.18.4 Antejin Biotechnology Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.18.5 Antejin Biotechnology Recent Development
11.19 Lanzhou Institute of Biological Products
11.19.1 Lanzhou Institute of Biological Products Company Details
11.19.2 Lanzhou Institute of Biological Products Business Overview
11.19.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Introduction
11.19.4 Lanzhou Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.19.5 Lanzhou Institute of Biological Products Recent Development
11.20 Wuhan Institute of Biological Products
11.20.1 Wuhan Institute of Biological Products Company Details
11.20.2 Wuhan Institute of Biological Products Business Overview
11.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Introduction
11.20.4 Wuhan Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.20.5 Wuhan Institute of Biological Products Recent Development
11.21 Beijing Institute of Biological Products
11.21.1 Beijing Institute of Biological Products Company Details
11.21.2 Beijing Institute of Biological Products Business Overview
11.21.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Introduction
11.21.4 Beijing Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.21.5 Beijing Institute of Biological Products Recent Development
11.22 Chengdu Institute of Biological Products
11.22.1 Chengdu Institute of Biological Products Company Details
11.22.2 Chengdu Institute of Biological Products Business Overview
11.22.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Introduction
11.22.4 Chengdu Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2019-2024)
11.22.5 Chengdu Institute of Biological Products Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Merck & Co.
Pfizer
Sanofi Pasteur
GlaxoSmithKline
BioNTech
Moderna
Dynavax
Novavax
Sino Biopharm
Kangtai Bio
Zhifei Biological
Walvax
Minhai Biological
Sinovac
Wantai Biological
Wanbangde Pharmaceutical
AIM Bio
Antejin Biotechnology
Lanzhou Institute of Biological Products
Wuhan Institute of Biological Products
Beijing Institute of Biological Products
Chengdu Institute of Biological Products
听
听
*If Applicable.